Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development (2023 - 2025)

CG Oncology (CGON) has disclosed Research & Development for 3 consecutive years, with $30.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 11.78% year-over-year to $30.0 million, compared with a TTM value of $116.6 million through Dec 2025, up 42.07%, and an annual FY2025 reading of $116.6 million, up 42.07% over the prior year.
  • Research & Development was $30.0 million for Q4 2025 at CG Oncology, up from $27.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.3 million in Q2 2025 and bottomed at $7.8 million in Q1 2023.
  • Average Research & Development over 3 years is $20.4 million, with a median of $19.0 million recorded in 2024.
  • The sharpest move saw Research & Development soared 119.46% in 2024, then grew 11.78% in 2025.
  • Year by year, Research & Development stood at $16.3 million in 2023, then surged by 64.01% to $26.8 million in 2024, then grew by 11.78% to $30.0 million in 2025.
  • Business Quant data shows Research & Development for CGON at $30.0 million in Q4 2025, $27.9 million in Q3 2025, and $31.3 million in Q2 2025.